Navigation Links
Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment
Date:10/22/2008

COPENHAGEN, October 22 /PRNewswire-FirstCall/ -- Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment.

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of GRAZAX(R) persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a persistent, positive effect on the immune system indicating a lasting tolerance to grass pollen.

During the first year after completion of treatment, GRAZAX(R) continues to provide statistically significant reductions in both hay fever symptoms and the use of symptom-relieving medication.

In the follow-up year, hay fever symptoms were reduced by 31% while the use of symptom-relieving medication was reduced by 52%. The reduction of symptoms and use of medication is measured as median values relative to a control group in which patients had unrestricted access to symptom-relieving medication.

The patients in the study have adhered to the recommended three-year GRAZAX(R) treatment regimen and completed treatment in the autumn of 2007. The above-mentioned results cover the 2008 pollen season, the first season in which the patients did not receive active treatment with GRAZAX(R).

The fourth-year results represent a major breakthrough, since ALK is the first company ever to document a persistent disease modifying vaccination effect of a tablet-based allergy vaccine. Patients cannot obtain such a persistent vaccination effect with traditional symptom-relieving allergy medication.
ALK-Abelló A/S - Company release No 14/2008 - October 22, 2008

ALK-Abelló A/S

Jens Bager

President and CEO

For further information please contact:

Jens Bager, President and CEO, tel. +45-4575-7576

Investor Relations: Per Plotnikof, tel +45-4574-7527, mobile +45-2261-2525

Press: Jacob Frische, tel +45-4574-7551, mobile +45-2224-7551


'/>"/>
SOURCE ALK-Abello A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Phase III Trial Finds Pharmaxis Bronchitol Effective
3. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
4. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
5. New nanoparticle vaccine is more effective but less expensive
6. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock ... Global Forecast to 2022", published by MarketsandMarkets, the global market is estimated to ... 1,399.6 Million by 2022, at a CAGR of 6.96% from 2016. ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... 11, 2017 , ... Ovation Fertility™ Genetics now offers a ... screening (PGS). , “Our genetics and IVF teams are recognized experts in both ... Amy Jones, M.S., ELD (ABB) , who has worked with or directed ...
(Date:1/11/2017)... , Jan. 11, 2017  Brian Mehling, M.D., world-renowned ... of Blue Horizon International (BHI), will be attending the ... Davos from January 17-20, 2017. This will ... The theme of this year,s forum is ... 400 sessions will address strategies for fostering greater social ...
(Date:1/11/2017)... San Francisco, CA (PRWEB) , ... January 11, ... ... ongoing series of in-kind scientific grants to ground-breaking microbiome studies. Its most recent ... University School of Medicine, who will study the effect of long-term use of ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
Breaking Biology News(10 mins):